Multi-Omics Analysis of the Anti-tumor Synergistic Mechanism and Potential Application of Immune Checkpoint Blockade Combined With Lenvatinib
Open Access
- 9 September 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
Abstract
The combination of immune-checkpoint blockade (ICB) and lenvatinib has demonstrated robust clinical effects that are superior to those of monotherapies, but the synergistic anti-tumor mechanisms remain unclear. Exploring the synergistic molecular mechanisms and early identifying potential application have key importance for clinical therapeutics. We firstly systematically reviewed published data of ICB in combination with lenvatinib for the treatment of cancer by meta-analysis. A subsequent bioinformatics analysis explored the mechanism of combined ICB and lenvatinib therapy in 33 cancer types. Transcriptomic analysis was conducted by RNA-seq, and genomic analysis was performed on gene mutations and copy-number alteration data. Tumor-related pathways and tumor immune micro-environment (TIME) were also investigated. The meta-analysis showed a 38.0% objective response rate (ORR) and 79% disease control rate (DCR) for ICB combined with lenvatinib. Multi-omics analysis revealed that ICB and lenvatinib target genes were highly expressed and showed driving alterations in six specific malignancies. Pathway-enrichment analysis found target genes were implicated in tumor development, angiogenesis, and immunoregulatory associated pathways. This study verified the potential synergistic mechanisms of ICB combined with lenvatinib at transcriptomics, genomics, protein, and cellular levels and recognized nine tumor types had ≥ 2 positive treatment-related molecular characteristics, which might benefit particularly from this combined strategy. The findings would help to provide clinical insights and theoretical basis for optimizing of targeted therapy-immunotherapy combinations, and for guiding individualized precision-medicine approaches for cancer treatment.Keywords
Funding Information
- National Natural Science Foundation of China
- Research Foundation of Beijing Friendship Hospital, Capital Medical University (No. yyzscq202003)
This publication has 75 references indexed in Scilit:
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer ProgressionCell, 2015
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialThe Lancet Oncology, 2015
- Regulation of T cells by mTOR: the known knowns and the known unknownsTrends in Immunology, 2014
- Targeting molecular pathways in endometrial cancer: A focus on the FGFR pathwayCancer Treatment Reviews, 2014
- Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinibBiologics: Targets and Therapy, 2014
- Mutational heterogeneity in cancer and the search for new cancer-associated genesNature, 2013
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumoursBritish Journal of Cancer, 2012
- YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity in vitro and in vivoCancer Science, 2011
- Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitroAngiogenesis, 2004
- Imatinib As a Paradigm of Targeted TherapiesJournal of Clinical Oncology, 2003